Works by CHERNEY, DAVID


Results: 217
    1
    2
    3

    Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2025, v. 27, n. 8, p. 4415, doi. 10.1111/dom.16478
    By:
    • Beernink, Jelle M.;
    • Jongs, Niels;
    • Mosterd, Charlotte M.;
    • Scholtes, Rosalie A.;
    • Caldwell‐McGee, Alyssa;
    • Casillas, Daniel;
    • Driscoll, Lynette;
    • Greasley, Peter J.;
    • Karlsson, Cecilia;
    • Hammarstedt, Ann;
    • Sridhar, Vikas S.;
    • Muskiet, Marcel H. A.;
    • Laverman, Gozewijn D.;
    • Cherney, David Z. I.;
    • Bjornstad, Petter;
    • van Raalte, Daniel H.;
    • Heerspink, Hiddo J. L.
    Publication type:
    Article
    4
    5

    Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double‐blind trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2025, v. 27, n. 7, p. 3943, doi. 10.1111/dom.16431
    By:
    • van Baar, Michaël J. B.;
    • Muskiet, Marcel H. A.;
    • Scholtes, Rosalie A.;
    • Touw, Daan J.;
    • Nieuwdorp, Max;
    • Kramer, Mark H. H.;
    • Joles, Jaap A.;
    • Cherney, David Z. I.;
    • Bjornstad, Petter;
    • Krebber, Merle M.;
    • van Raalte, Daniël H.
    Publication type:
    Article
    6
    7
    8
    9

    Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4261, doi. 10.1111/dom.15769
    By:
    • Zheng, Katina;
    • Azhie, Amirhossein;
    • You, Xiaoting;
    • Naghibzadeh, Maryam;
    • Tan, Eunice;
    • Naimimohasses, Sara;
    • Sridhar, Vikas S.;
    • Gupta, Sarang;
    • Chen, Shiyi;
    • Dash, Satya;
    • Tsien, Cynthia;
    • Selzner, Nazia;
    • Lilly, Leslie;
    • Jaeckel, Elmar;
    • Woo, Minna;
    • Singh, Sunita;
    • Cherney, David;
    • Bhat, Mamatha
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17

    Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
    By:
    • Kim, Joseph M.;
    • Bhatt, Deepak L.;
    • Dagogo‐Jack, Samuel;
    • Cherney, David Z. I.;
    • Cosentino, Francesco;
    • McGuire, Darren K.;
    • Pratley, Richard E.;
    • Liu, Chih‐Chin;
    • Cater, Nilo B.;
    • Frederich, Robert;
    • Mancuso, James P.;
    • Cannon, Christopher P.
    Publication type:
    Article
    18

    Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
    By:
    • Corbin, Karen D.;
    • Dagogo‐Jack, Samuel;
    • Cannon, Christopher P.;
    • Cherney, David Z.I.;
    • Cosentino, Francesco;
    • Frederich, Robert;
    • Liu, Jie;
    • Pong, Annpey;
    • Lin, Jianxin;
    • Cater, Nilo B.;
    • Pratley, Richard E.
    Publication type:
    Article
    19

    Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
    By:
    • Segar, Matthew W.;
    • Kolkailah, Ahmed A.;
    • Frederich, Robert;
    • Pong, Annpey;
    • Cannon, Christopher P.;
    • Cosentino, Francesco;
    • Dagogo‐Jack, Samuel;
    • McGuire, Darren K.;
    • Pratley, Richard E.;
    • Liu, Chih‐Chin;
    • Maldonado, Mario;
    • Liu, Jie;
    • Cater, Nilo B.;
    • Pandey, Ambarish;
    • Cherney, David Z. I.
    Publication type:
    Article
    20

    Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1578, doi. 10.1111/dom.14729
    By:
    • Sen, Taha;
    • Scholtes, Rosalie;
    • Greasley, Peter J.;
    • Cherney, David Z. I.;
    • Dekkers, Claire C. J.;
    • Vervloet, Marc;
    • Danser, Alexander H. J.;
    • Barbour, Sean J.;
    • Karlsson, Cecilia;
    • Hammarstedt, Ann;
    • Li, Qiang;
    • Laverman, Gozewijn D.;
    • Bjornstad, Petter;
    • van Raalte, Daniel H.;
    • Heerspink, Hiddo J. L.
    Publication type:
    Article
    21
    22
    23
    24
    25

    Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1961, doi. 10.1111/dom.14411
    By:
    • van der Aart‐van der Beek, Annemarie B.;
    • Cherney, David;
    • Laverman, Gozewijn D.;
    • Stefansson, Bergur;
    • Raalte, Daniel H.;
    • Hoogenberg, Klaas;
    • Reyner, Daniel;
    • Li, Qiang;
    • Di Tanna, Gian Luca;
    • Greasley, Peter J.;
    • Heerspink, Hiddo J. L.
    Publication type:
    Article
    26

    Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1956, doi. 10.1111/dom.14401
    By:
    • Khunti, Kamlesh;
    • Charbonnel, Bernard;
    • Chen, Hungta;
    • Cherney, David Z.;
    • Cooper, Andrew;
    • Fenici, Peter;
    • Gomes, Marilia B.;
    • Hammar, Niklas;
    • Heerspink, Hiddo J. L.;
    • Ji, Linong;
    • Medina, Jesús;
    • Nicolucci, Antonio;
    • Ramirez, Larisa;
    • Rathmann, Wolfgang;
    • Shestakova, Marina V.;
    • Shimomura, Iichiro;
    • Tang, Fengming;
    • Watada, Hirotaka;
    • Kosiborod, Mikhail
    Publication type:
    Article
    27
    28
    29

    Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes.

    Published in:
    Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1388, doi. 10.1111/dom.13665
    By:
    • Lytvyn, Yuliya;
    • Singh, Sunita K.;
    • Lai, Vesta;
    • Tse, Josephine;
    • Cham, Leslie;
    • Cherney, David Z. I.;
    • Advani, Andrew;
    • Sochett, Etienne;
    • Bjornstad, Petter;
    • Lovshin, Julie A.;
    • Boulet, Genevieve;
    • Farooqi, Mohammed A.;
    • Weisman, Alanna;
    • Perkins, Bruce A.;
    • Lovblom, Leif E.;
    • Keenan, Hillary A.;
    • Brent, Michael H.;
    • Paul, Narinder;
    • Bril, Vera
    Publication type:
    Article
    30
    31

    The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.

    Published in:
    Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 575, doi. 10.1111/dom.13556
    By:
    • Bjornstad, Petter;
    • Singh, Sunita K.;
    • Snell‐Bergeon, Janet K.;
    • Lovshin, Julie A.;
    • Lytvyn, Yuliya;
    • Lovblom, Leif E.;
    • Rewers, Marian J.;
    • Boulet, Genevieve;
    • Lai, Vesta;
    • Tse, Josephine;
    • Cham, Leslie;
    • Orszag, Andrej;
    • Weisman, Alanna;
    • Keenan, Hillary A.;
    • Brent, Michael H.;
    • Paul, Narinder;
    • Bril, Vera;
    • Perkins, Bruce A.;
    • Cherney, David Z. I.
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39

    Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.

    Published in:
    Nephrology Dialysis Transplantation, 2025, v. 40, n. 2, p. 308, doi. 10.1093/ndt/gfae132
    By:
    • Heerspink, Hiddo J L;
    • Agarwal, Rajiv;
    • Bakris, George L;
    • Cherney, David Z I;
    • Lam, Carolyn S P;
    • Neuen, Brendon L;
    • Sarafidis, Pantelis A;
    • Tuttle, Katherine R;
    • Wanner, Christoph;
    • Brinker, Meike D;
    • Dizayee, Sara;
    • Kolkhof, Peter;
    • Schloemer, Patrick;
    • Vesterinen, Paula;
    • Perkovic, Vlado;
    • investigators, for the FIND-CKD
    Publication type:
    Article
    40
    41
    42
    43

    The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.

    Published in:
    Nephrology Dialysis Transplantation, 2020, v. 35, n. 10, p. 1700, doi. 10.1093/ndt/gfaa234
    By:
    • Wheeler, David C;
    • Stefansson, Bergur V;
    • Batiushin, Mikhail;
    • Bilchenko, Oleksandr;
    • Cherney, David Z I;
    • Chertow, Glenn M;
    • Douthat, Walter;
    • Dwyer, Jamie P;
    • Escudero, Elizabeth;
    • Pecoits-Filho, Roberto;
    • Furuland, Hans;
    • Górriz, José Luis;
    • Greene, Tom;
    • Haller, Hermann;
    • Hou, Fan Fan;
    • Kang, Shin-Wook;
    • Isidto, Rey;
    • Khullar, Dinesh;
    • Mark, Patrick B;
    • McMurray, John J V
    Publication type:
    Article
    44

    The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.

    Published in:
    Nephrology Dialysis Transplantation, 2020, v. 35, n. 5, p. 895, doi. 10.1093/ndt/gfz294
    By:
    • Opingari, Erika;
    • Verma, Subodh;
    • Connelly, Kim A;
    • Mazer, Cyril David;
    • Teoh, Hwee;
    • Quan, Adrian;
    • Zuo, Fei;
    • Pan, Yi;
    • Bhatt, Deepak L;
    • Zinman, Bernard;
    • Leiter, Lawrence A;
    • Yan, Andrew T;
    • Cherney, David Z I;
    • Gilbert, Richard E
    Publication type:
    Article
    45
    46
    47
    48
    49

    Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes.

    Published in:
    Renal Failure, 2019, v. 41, n. 1, p. 427, doi. 10.1080/0886022X.2019.1614057
    By:
    • Sekercioglu, Nigar;
    • Lovblom, Leif Erik;
    • Bjornstad, Petter;
    • Lovshin, Julie A.;
    • Lytvyn, Yuliya;
    • Boulet, Geneviève;
    • Farooqi, Mohammed A.;
    • Orszag, Andrej;
    • Lai, Vesta;
    • Tse, Josephine;
    • Cham, Leslie;
    • Keenan, Hillary A.;
    • Brent, Michael H.;
    • Paul, Narinder;
    • Bril, Vera;
    • Perkins, Bruce A.;
    • Cherney, David Z. I.
    Publication type:
    Article
    50